Teva Pays Out A Further $1m On Intuniv

Also Gets 2029 Entry Date On 72mcg Linaclotide Via Settlement

 
• By Dave Wallace

Teva will pay out more than $1m as part of a settlement deal over Intuniv (guanfacine) involving indirect purchasers, newly-filed court documents reveal. Meanwhile, the firm has also just gained a 2029 entry date for a 72mcg strength of its linaclotide rival to Linzess through a separate settlement.

Million dollars cash pile notes money
The Intuniv settlement fund for indirect purchasers will total $1.1m • Source: Alamy

More from Deals

More from Business